Summary and opinion by Wendy Anderson.
A Congressional panel has shown their disregard for the health of the U.S. public by completely rejecting three amendments set forward last week by Dana Rohrahbacher (R-CA) and Jared Polis (D-CO).
The first amendment would have conducted the task force, such as the Drug Enforcement Agency, The Office of National Drug Control Policy, and the Food and Drug Administration, to study the potential for cannabis to serve as an alternative to opioids as pain management.
The second amendment would’ve required a study by the National Institutes of Health and the Center of Disease Control on the medical application of cannabis and opioids. It would’ve also necessitated the federal comparison of opioid overdose deaths between states which have legalized cannabis and those that haven’t.
The third proposed amendment was sponsored by Reps. Scott Perry (R-PA) and Bob Dold (R-IL), as well as with Polis, would’ve excluded cannabis plants high in CBD and low in THC from the federal definition of marijuana. These are plants that are rich in Cannabidiol such as the Charlette’s Web used for children with the severe form of epilepsy Dravet Syndrome.
The committee ruled all three out of order, which means they could not even be offered a vote on the floor. Not even a chance.
However, when the bill was put to vote after the all of the amendments were taken out it was passed right through. Meaning they are all in the pharmaceutical pocket and out of the interest of science and health of the people they are supposed to represent. This is not a shining move for this U.S. House Rules Committee especially the ones bragging on social media.
Read the original article here.
Comments will be approved before showing up.
Liquid error: Could not find asset snippets/mailchimp-popup.liquid